Broccoli Sprout Intervention in Qidong, P.R. China
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01437501|
Recruitment Status : Completed
First Posted : September 21, 2011
Results First Posted : September 23, 2013
Last Update Posted : August 16, 2018
|Condition or disease||Intervention/treatment||Phase|
|Environmental Carcinogenesis||Drug: Broccoli Sprout Extract Beverage Drug: placebo beverage||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||291 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Broccoli Sprout Intervention in Qidong, P.R. China|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||January 2012|
|Actual Study Completion Date :||January 2012|
|Experimental: Broccoli Sprout Extract Beverage||
Drug: Broccoli Sprout Extract Beverage
Broccoli Sprout Extract Beverage: 600 micromole glucoraphanin and 40 micromole sulforaphane dissolved in 100 mL dilute pineapple and lime juice daily for 84 days.
|Placebo Comparator: Placebo beverage||
Drug: placebo beverage
100 mL of dilute pineapple and lime juice daily for 84 days.
- Effect of Treatment on Levels of Air Toxics Mercapturic Acids Over Intervention Period [ Time Frame: Endpoints were assessed on urine samples collected at the end of the intervention on week 12. ]Urinary excretion of benzene mercapturic acid (S-PMA) in 12 hour overnight void at 12 weeks
- Levels of Sulforaphane and Its Metabolites at the End of Intervention Period (After 84 Daily Doses) [ Time Frame: Endpoints assessed on urine samples collected at the end of the intervention (day 84 [week 12]) ]Micromoles of urinary sulforaphane metabolites excreted over 24 hours after consuming the 84th dose.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01437501
|Qidong Liver Cancer Institute|
|Qidong, Jiangsu, China, 226200|
|Principal Investigator:||Thomas W Kensler, PhD||Johns Hopkins Bloomberg School of Public Health|